Arix Bioscience
plc
Notice of Annual
General Meeting
Announcement of
format of 2020 Annual General Meeting
LONDON, 12 May 2020: Arix Bioscience plc (“Arix” or
the ”Company”) (LSE: ARIX), a global venture capital company
focused on investing in and building breakthrough biotech
companies, today announces that its Annual General Meeting (“AGM”)
will be held at the Company's offices at 20 Berkeley Square,
London, W1J 6EQ from 2:00pm on Thursday 4 June
2020.
Notice of the AGM and the Form of Proxy were posted to
shareholders on 7 May 2020. In
compliance with Listing Rule 9.6.1, these documents have today been
submitted to the National Storage Mechanism and will shortly be
available for inspection at www.morningstar.co.uk/uk/nsm.
In accordance with UK Government instructions issued on
23 March 2020, it is regretted that
shareholders must not attend the AGM in person but are
encouraged to submit their vote by proxy by 2.00pm BST on
Tuesday 2 June 2020. Details of the
procedure for doing so are set out in the Notice of Meeting which
has been posted to shareholders and is available on the Company’s
website.
The Directors believe that the resolutions to be put to the
meeting are in the best interests of the Company and its
shareholders as a whole, and unanimously recommend that that
shareholders vote in favour of all proposed resolutions.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor
Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Robert Lyne, Company
Secretary
+44 (0)20 7290 1055
robert@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam
Bashir
+44 (0)20 3950 9144
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com